Dr. Neelesh Sharma is chief medical officer of Vivace Therapeutics. He brings extensive experience in oncology clinical drug development and proven leadership in biotech and pharmaceutical industries. Prior to joining Vivace, he was Senior Vice President of Clinical Development at Prelude Therapeutics. He spent several years at Bayer pharmaceutical as Vice President and Head of Precision Oncology, leading early development portfolio of drugs as well as late-stage studies of regorafenib combination with checkpoint inhibitors. Prior to joining Bayer, he held senior clinical leadership role at Novartis and led early development teams for a variety of programs. His meaningful contributions resulted in the approval of infigratinib for cholangiocarcinoma and larotrectinib for solid tumors, representing notable milestones in precision oncology. Earlier in his career, Dr. Sharma served several years in academia as a thoracic oncologist and phase 1 trialist at the NCI designated Case Comprehensive Cancer Center in Cleveland, Ohio.  He completed a medical oncology fellowship at Roswell Park Cancer Center in Buffalo, NY and internal medicine training at John H. Stroger Hospital of Rush University, Chicago. Dr. Sharma completed his medical education at GSVM Medical College, India, and received a Ph.D. in Toxicology and Pharmacology at the University of Georgia, USA.